Fr173657

Icatibant (peptide kinin B₂ receptor antagonist) and des-Arg⁹-[Leu⁸]-bradykinin (DALBk; peptide kinin B₁ receptor antagonist) were obtained from Sigma Chemical Company (St. Louis, MO, USA). FR173657 (non-peptide kinin B₂ receptor antagonist) and SSR240612 (non-peptide kinin B₁ receptor antagonist) were obtained from Sanofi-Aventis (Germany). Aprotinin was acquired from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Kinin receptor antagonists and Aprotinin were prepared in a saline solution (0.9% NaCl), which was used as the vehicle in control groups. The enzyme immunoassay kit for bradykinin was obtained from Peninsula Laboratories International, Inc. (San Carlos, CA, USA). The doses of the drugs used in this study were based on pilot experiments or previous studies. They were administered in a volume of 10 mL/kg (systemic administration) or 20 μL/paw (intraplantar injection) [22 (link),23 (link)].

Cisplatin (cis-diamminedichloridoplatinum II, C-Platin^®; Blau, SP, Brazil), bradykinin (Bk; kinin B₂ receptor agonist), Icatibant (peptide kinin B₂ receptor antagonist), des-Arg⁹-bradykinin (DABk; kinin B₁ receptor agonist), and des-Arg⁹-[Leu⁸]-bradykinin (DALBK; peptide kinin B₁ receptor antagonist) were purchased from Sigma Chemical Company (St. Louis, MO, USA). FR173657 (non-peptide kinin B₂ receptor antagonist) and SSR240612 (non-peptide kinin B₁ receptor antagonist) were obtained from Sanofi-Aventis (Berlin, Germany). Antisense oligonucleotides targeting the kinin B₁ receptor (5′-AGG TTC CTG TGG ATG GCG TCCC-3′), kinin B₂ receptor (5′-AGA ATT CTG TTC ACT GTT TCT TCC CTG-3′), and nonsense oligonucleotides (5′-GGT GGA T TTG AGG ATT TCG GC-3′) were acquired from GenOne Biotechnologies (Rio de Janeiro, Brazil). Cisplatin and antagonists were prepared in a saline solution (0.9%). Phosphate-buffered saline (PBS; 10 mM) was used to dilute reagents administered via the intraplantar route (kinin B₁ and B₂ receptor agonists). The control groups (vehicles) received the vehicles where the treatments were solubilized. All the intraperitoneal treatments were administered in mice in a volume of 10 mL/kg, while intraplantar injections were administered in a volume of 20 µL.